Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CERE | Stock Option (Right to Buy) | Award | $0 | +79K | $0.00 | 79K | Feb 6, 2023 | Common Stock | 79K | $34.41 | Direct | F1 | |
transaction | CERE | Restricted Stock Units | Award | $0 | +20.1K | $0.00 | 20.1K | Feb 6, 2023 | Common Stock | 20.1K | Direct | F2, F3 |
Id | Content |
---|---|
F1 | 25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
F2 | The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. |
F3 | The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date. |